Radiogenomics predicting tumor responses to radiotherapy in lung cancer

Amit K. Das, Marcus H. Bell, Chaitanya S. Nirodi, Michael D. Story, John D. Minna

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

The recently developed ability to interrogate genome-wide data arrays has provided invaluable insights into the molecular pathogenesis of lung cancer. These data have also provided information for developing targeted therapy in lung cancer patients based on the identification of cancer-specific vulnerabilities and set the stage for molecular biomarkers that provide information on clinical outcome and response to treatment. In addition, there are now large panels of lung cancer cell lines, both non-small-cell lung cancer and small-cell lung cancer, that have distinct chemotherapy and radiation response phenotypes. We anticipate that the integration of molecular data with therapy response data will allow for the generation of biomarker signatures that predict response to therapy. These signatures will need to be validated in clinical studies, at first retrospective analyses and then prospective clinical trials, to show that the use of these biomarkers can aid in predicting patient outcomes (eg, in the case of radiation therapy for local control and survival). This review highlights recent advances in molecular profiling of tumor responses to radiotherapy and identifies challenges and opportunities in developing molecular biomarker signatures for predicting radiation response for individual patients with lung cancer.

Original languageEnglish (US)
Pages (from-to)149-155
Number of pages7
JournalSeminars in Radiation Oncology
Volume20
Issue number3
DOIs
StatePublished - Jul 2010

Fingerprint

Lung Neoplasms
Radiotherapy
Biomarkers
Neoplasms
Radiation
Small Cell Lung Carcinoma
Therapeutics
Non-Small Cell Lung Carcinoma
Clinical Trials
Genome
Phenotype
Drug Therapy
Cell Line
Survival

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Cite this

Radiogenomics predicting tumor responses to radiotherapy in lung cancer. / Das, Amit K.; Bell, Marcus H.; Nirodi, Chaitanya S.; Story, Michael D.; Minna, John D.

In: Seminars in Radiation Oncology, Vol. 20, No. 3, 07.2010, p. 149-155.

Research output: Contribution to journalArticle

Das, Amit K. ; Bell, Marcus H. ; Nirodi, Chaitanya S. ; Story, Michael D. ; Minna, John D. / Radiogenomics predicting tumor responses to radiotherapy in lung cancer. In: Seminars in Radiation Oncology. 2010 ; Vol. 20, No. 3. pp. 149-155.
@article{4b475aa8956745d7b06b14b4ebca18ce,
title = "Radiogenomics predicting tumor responses to radiotherapy in lung cancer",
abstract = "The recently developed ability to interrogate genome-wide data arrays has provided invaluable insights into the molecular pathogenesis of lung cancer. These data have also provided information for developing targeted therapy in lung cancer patients based on the identification of cancer-specific vulnerabilities and set the stage for molecular biomarkers that provide information on clinical outcome and response to treatment. In addition, there are now large panels of lung cancer cell lines, both non-small-cell lung cancer and small-cell lung cancer, that have distinct chemotherapy and radiation response phenotypes. We anticipate that the integration of molecular data with therapy response data will allow for the generation of biomarker signatures that predict response to therapy. These signatures will need to be validated in clinical studies, at first retrospective analyses and then prospective clinical trials, to show that the use of these biomarkers can aid in predicting patient outcomes (eg, in the case of radiation therapy for local control and survival). This review highlights recent advances in molecular profiling of tumor responses to radiotherapy and identifies challenges and opportunities in developing molecular biomarker signatures for predicting radiation response for individual patients with lung cancer.",
author = "Das, {Amit K.} and Bell, {Marcus H.} and Nirodi, {Chaitanya S.} and Story, {Michael D.} and Minna, {John D.}",
year = "2010",
month = "7",
doi = "10.1016/j.semradonc.2010.01.002",
language = "English (US)",
volume = "20",
pages = "149--155",
journal = "Seminars in Radiation Oncology",
issn = "1053-4296",
publisher = "W.B. Saunders Ltd",
number = "3",

}

TY - JOUR

T1 - Radiogenomics predicting tumor responses to radiotherapy in lung cancer

AU - Das, Amit K.

AU - Bell, Marcus H.

AU - Nirodi, Chaitanya S.

AU - Story, Michael D.

AU - Minna, John D.

PY - 2010/7

Y1 - 2010/7

N2 - The recently developed ability to interrogate genome-wide data arrays has provided invaluable insights into the molecular pathogenesis of lung cancer. These data have also provided information for developing targeted therapy in lung cancer patients based on the identification of cancer-specific vulnerabilities and set the stage for molecular biomarkers that provide information on clinical outcome and response to treatment. In addition, there are now large panels of lung cancer cell lines, both non-small-cell lung cancer and small-cell lung cancer, that have distinct chemotherapy and radiation response phenotypes. We anticipate that the integration of molecular data with therapy response data will allow for the generation of biomarker signatures that predict response to therapy. These signatures will need to be validated in clinical studies, at first retrospective analyses and then prospective clinical trials, to show that the use of these biomarkers can aid in predicting patient outcomes (eg, in the case of radiation therapy for local control and survival). This review highlights recent advances in molecular profiling of tumor responses to radiotherapy and identifies challenges and opportunities in developing molecular biomarker signatures for predicting radiation response for individual patients with lung cancer.

AB - The recently developed ability to interrogate genome-wide data arrays has provided invaluable insights into the molecular pathogenesis of lung cancer. These data have also provided information for developing targeted therapy in lung cancer patients based on the identification of cancer-specific vulnerabilities and set the stage for molecular biomarkers that provide information on clinical outcome and response to treatment. In addition, there are now large panels of lung cancer cell lines, both non-small-cell lung cancer and small-cell lung cancer, that have distinct chemotherapy and radiation response phenotypes. We anticipate that the integration of molecular data with therapy response data will allow for the generation of biomarker signatures that predict response to therapy. These signatures will need to be validated in clinical studies, at first retrospective analyses and then prospective clinical trials, to show that the use of these biomarkers can aid in predicting patient outcomes (eg, in the case of radiation therapy for local control and survival). This review highlights recent advances in molecular profiling of tumor responses to radiotherapy and identifies challenges and opportunities in developing molecular biomarker signatures for predicting radiation response for individual patients with lung cancer.

UR - http://www.scopus.com/inward/record.url?scp=77954853984&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77954853984&partnerID=8YFLogxK

U2 - 10.1016/j.semradonc.2010.01.002

DO - 10.1016/j.semradonc.2010.01.002

M3 - Article

VL - 20

SP - 149

EP - 155

JO - Seminars in Radiation Oncology

JF - Seminars in Radiation Oncology

SN - 1053-4296

IS - 3

ER -